Araris Biotech enters research collaboration with Taiho Pharma to develop next-generation ADCs using Araris’ proprietary linker-conjugation technology

Araris Biotech AG (Araris), a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), announced they have entered a collaboration agreement under which Araris will use its proprietary linker-conjugation platform to generate novel ADCs against undisclosed targets provided by Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma company with a focus on oncology.

ADCs delivered by Araris will be further tested and evaluated by Taiho. The financial terms of the collaboration agreement were not disclosed.

“We are proud to enter a collaboration with Taiho Pharmaceutical and look forward to working with the Taiho team to develop next-generation ADCs with improved efficacy and tolerability,” said Dragan Grabulovski, Ph.D., acting chief executive officer of Araris.

Philipp Spycher, Ph.D., chief scientific officer of Araris added, “This agreement underlines the potential of our linker-payload platform to deliver novel ADCs with excellent properties, and it positions our company as a highly attractive partner for pharmaceutical companies.”

Araris Biotech is a pioneering leader in the development of antibody-drug conjugates (ADCs) with the potential for unparalleled efficacy and tolerability. With a strong commitment to transforming the landscape of ADCs, Araris leverages its proprietary, ready-to-use linker-payload platforms and site-specific conjugation techniques to create a new frontier in targeted therapeutics.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!